Sanovel in International Markets
Being a leader in the pharmaceutical sector of Turkey, Sanovel takes uncompromising efforts in developing products of highest quality to global standards and becoming a thought leader in the sector. Sanovel also possesses one of the largest factories in Europe and has obtained GMP authorisation from the authorising bodies of various countries, following rigorous and comprehensive inspections. The company initiated its export activities by entering the Commonwealth of Independent States market in 2004 and subsequently began exporting its products to Europe in 2011. Currently it exports to several markets like the United States, Canada, Spain,Georgia, Azerbaijan, Kazakhstan, Kyrgyzstan, Uzbekistan, Russia, Iraq, Albania and Turkmenistan.
The regulatory team, in coordination with the Sanovel’s Business Development, International Operations, R&D, Licensing, Intellectual Property and Legal Functions, helps create new business opportunities for the company, in new geographies.
Obtaining ANDA approval in the year 2019, Sanovel became the only Turkish pharmaceutical manufacturer that has the right to sell finished products in the US market. The company soon aims to increase its share in the rapidly growing international markets like the MENA, Southeast Asian, and LATAM.
There are over 100 marketing authorisations expected to be approved in more than 20 new international markets, in the near future. Each day, Sanovel aims to reach more patients across the world with the help of its agile R&D, IP, Quality and Business Development teams which put the patients at the center, adapting quickly to change, at a global scale.